Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy

OBJECTIVE: To determine whether the benefits of dapagliflozin in patients with heart failure and reduced ejection fraction (HFrEF) and type 2 diabetes in the Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure trial (DAPA-HF) varied by background glucose-lowering therapy (GLT). RESEARC...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetes Care
Main Authors: Docherty, Kieran F., Jhund, Pardeep S., Bengtsson, Olof, DeMets, David L., Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Langkilde, Anna Maria, Martinez, Felipe A., Sabatine, Marc S., Sjöstrand, Mikaela, Solomon, Scott D., McMurray, John J.V.
Formato: Artigo
Idioma:Inglês
Publicado em: American Diabetes Association 2020
Assuntos:
Novel Communications in Diabetes
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7809714/
https://ncbi.nlm.nih.gov/pubmed/33082245
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc20-1402
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados